A Phase IA/IB Study Evaluating TAS-116 in Patients With Advanced Solid Tumors
A Phase IA/IB Study Evaluating TAS-116 in Patients With Advanced Solid Tumors is a PHASE1 clinical asset sponsored by Taiho Oncology, Inc. in Advanced Solid Tumors. SEO and diligence focus: TAS-116, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Advanced Solid Tumors
Modality: small molecule
Target: TAS-116
Sponsor: Taiho Oncology, Inc.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 28, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: TAS-116
View original source fields
Condition raw: Advanced Solid Tumors
Condition normalized: Advanced Solid Tumors
Modality raw: small molecule
Modality normalized: small molecule
Target raw: TAS-116
Target normalized: TAS-116